Osteosarcoma: Current Treatment and a Collaborative Pathway to Success

Abstract

Osteosarcoma is the bone tumor that most commonly affects children, adolescents, and young adults. Before 1970, treatment primarily included surgical resection. However, the introduction of chemotherapy led to a dramatic improvement in prognosis for patients with localized osteosarcoma; long-term survival rates of less than 20% improved to 65% to 70% after the advent of multiagent chemotherapy regimens. Controversy concerning the ideal combination of chemotherapy agents ensued throughout the last quarter of the 20th century because of conflicting and often nonrandomized data. However, large cooperative group studies and international collaboration have demonstrated that the most effective regimens include the combination of high-dose methotrexate, doxorubicin, and cisplatin (MAP). The introduction of biologic agents such as muramyl tripeptide and the use of additional cytotoxic chemotherapy such as ifosfamide have not definitively improved the survival of patients with osteosarcoma. Collaborative efforts to increase understanding of the biology of osteosarcoma and the use of preclinical models to test novel agents will be critical to identify the path toward improving outcomes for patients. Once promising agents are identified, an international infrastructure exists for clinical trials. Herein, biologic, preclinical, and clinical trial efforts will be described along with future international collaborative strategies to improve outcomes for patients who develop this challenging tumor.

Conflict of interest statement

Authors' disclosures of potential conflicts of interest are found in the article online at www.jco.org. Author contributions are found at the end of this article.

© 2015 by American Society of Clinical Oncology.

Figures

Fig 1.

Event-free survival by clinical trial and year published for patients with nonmetastatic osteosarcoma.,,,– COSS, Cooperative German-Austrian-Swiss Osteosarcoma Study Group; INT, Intergroup study; IOR, Istituto Ortopedico Rizzoli; MIOS, Multi-Institutional Osteosarcoma Study; POG, Periatric Oncology Group; SFOP, Société Française d'Oncologie Pédiatrique.

Fig 2.

Event-free survival for patients with metastatic and localized disease enrolled onto the Children's Cancer Group/Pediatric Oncology Group Intergroup study INT0133 clinical trial.